Viral Hepatitis Patients Frequently Show Liver Disease
Nearly half of chronic hepatitis B and C patients in a large registry also suffer from metabolic liver disease.
Updated on Oct. 29, 2026 in Diseases — General
Live Poll
Should patients with chronic liver issues prioritize managing weight and diabetes to improve daily well-being?
A 2026 study of 4,649 patients from the Global Liver Registry identifies that metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent among those with chronic hepatitis B and C. Patients presenting with this dual diagnosis experience greater fatigue and reduced quality of life compared to those with viral hepatitis alone.
Why it matters
Understanding this high rate of overlap is vital for managing the health outcomes of the 287 million people globally living with chronic hepatitis B or C. These findings highlight a critical need for integrated screening and care pathways as the medical community addresses the 1.3 million annual deaths linked to these viral infections.
The analysis of 4,649 patients found MASLD in 49% of the 2,063 HBV cases and 47% of the 2,586 HCV cases, using a Hepatic Steatosis Index of 36 or higher as a metric. These rates underscore the co-morbidity burden among the 287 million people living with these infections.
The players
Global Liver Registry
This international research organization maintains a large database of clinical and patient-reported outcome data used to evaluate liver health.
The details
Researchers defined MASLD for the study by requiring a Hepatic Steatosis Index of 36 or higher in addition to at least one cardiometabolic risk factor. Patients managing both viral hepatitis and MASLD reported increased fatigue levels, emphasizing that the combination of these conditions significantly complicates patient health and daily functioning.
Timeline
2024: Estimated 287 million people lived with chronic HBV or HCV.
April 28, 2026: WHO published its global hepatitis report.
2026: Study on viral hepatitis and MASLD was published.
The Big Picture
The study findings expand upon the global burden of disease metrics highlighted in the WHO global hepatitis report.
Patients diagnosed with chronic hepatitis B or C should discuss metabolic screening with their physician to identify potential MASLD co-infections. Addressing these metabolic factors can potentially mitigate symptoms like persistent fatigue and improve overall quality of life.
The takeaway
Clinicians managing viral hepatitis should screen for metabolic conditions to better address the complex needs of their patients. Patients experiencing heightened fatigue should consult their healthcare provider about their metabolic health status alongside their existing hepatitis treatment plan.
Further reading
For additional context on chronic health conditions, see our Diseases — General section.
Live Poll
Should patients with chronic liver issues prioritize managing weight and diabetes to improve daily well-being?
